Fusion protein
By modifying the A and B chains of insulin with specific amino acids and fusing them with the Fc region of human IgG2, a stable insulin receptor agonist fusion protein is formed, which solves the problems of injection frequency and chemical stability in basal insulin therapy, achieves prolonged glycemic control and inhibition of hepatic glucose output, and improves patient compliance.
Patent Information
- Application Number
- CN202480077747.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-10-13
- Filing Date
- 2024-10-11
- Publication Date
- 2026-07-10
AI Technical Summary
Current basal insulin therapy requires daily injections, leading to poor patient compliance. Furthermore, existing insulin products lack sufficient chemical stability at room temperature, making them unsuitable for long-term storage.
An insulin receptor agonist fusion protein containing fusion into the human IgG2 Fc region was developed. By modifying the insulin A and B chains with specific amino acids and fusing them with the human IgG2 Fc region, homodimers or heterodimers were formed, thereby improving chemical stability and prolonging the duration of action.
It achieves chemical stability for long-term storage at room temperature, improves patient compliance by reducing the number of injections, and provides extended basal glucose control and hepatic glucose output inhibition.